---
title: PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
nct_id: NCT06186531
overall_status: UNKNOWN
phase: PHASE2
sponsor: NeuTherapeutics
study_type: INTERVENTIONAL
primary_condition: Menopause
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06186531.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06186531"
ct_last_update_post_date: 2024-01-02
last_seen_at: "2026-05-12T07:10:37.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health

**Official Title:** PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial

**NCT ID:** [NCT06186531](https://clinicaltrials.gov/study/NCT06186531)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 132
- **Lead Sponsor:** NeuTherapeutics
- **Collaborators:** University of Arizona
- **Conditions:** Menopause, Hot Flashes
- **Start Date:** 2023-11-17
- **Completion Date:** 2024-11-15
- **CT.gov Last Update:** 2024-01-02

## Brief Summary

This is a proof-of-concept phase 2 clinical trial to investigate the effect of the phytoestrogenic supplement PhytoSERM on vasomotor symptoms and other symptoms associated with the menopausal transition, and on blood-based biomarkers in peri- and postmenopausal women.

After the screening period, participants will be randomized to PhytoSERM 50 mg pills (administered orally, once per day) or matching placebo, 1:1 allocation, for a period of 12 weeks. After 12 weeks, all participants in the placebo group will be crossed-over to receive PhytoSERM pills for the remainder of the study (open-label phase).

## Detailed Description

This is a double-blinded, randomized, placebo-controlled, parallel designed, proof-of-concept phase 2 clinical trial to determine effect of PhytoSERM on vasomotor symptoms and other symptoms associated with the menopausal transition. PhytoSERM or placebo pills will be administered orally once a day over 24 weeks. Safety and tolerability will also be assessed over the duration of the study.

A total of 132 peri- or postmenopausal women aged 45-60 years and who are experiencing hot flashes will be enrolled in this trial. To determine eligibility, all participants will undergo cognitive assessment, physical assessment, ECG, clinical/safety laboratory assessment, and interviews. After a 2-week screening period, participants will be randomized to study intervention (PhytoSERM 50mg administered orally, once per day) or matching placebo, in a 1:1 allocation. After 12 weeks, participants in the placebo group will be crossed-over to PhytoSERM 50 mg for the remaining 12 weeks (open-label extension period). Hot flashes will be measured both objectively and subjectively. Objective data will be skin conductance levels collected via a wearable device that enables real-time physiological data acquisition, including activity and sleep data. Study participants will be asked to complete a total of 8 study visits. Study visits will occur at 4-week intervals after the baseline, except for visits # 6 and 7 (open-label period) which will occur at 6-week intervals after visit # 5 (final outcomes assessments visit). Visits 1, 2, 5 and 7 will last approximately 2-4 hours; visits 3, 4, 6 and 8 will last approximately 45 minutes.

All participants will be enrolled at a single site, at the University of Arizona (UA) Clinical \& Translational Sciences Research Center (CATS).

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 60 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Peri- or postmenopausal women, defined by any of the following:

  1. Last menstrual period (LMP) completed ≥ 60 days and ≤ 8 years, per the Stages of Reproductive Aging Workshop (STRAW) criteria.
  2. Post-hysterectomy or endometrial ablation ≥ 3 months and supported by FSH levels.
* Age 45-60 years.
* Presence of hot flashes ≥ 7 per day.
* Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be not clinically significant by the investigator.
* Mammogram within normal limits in the past 2 years: Breast Imaging Reporting and Data System (BI-RADS) category 1-2 or 3 with findings stable for 3 years.
* No medical contraindications to study participation.
* Stable medications for 4 weeks prior to the baseline visits.
* Ability to take oral medication and be willing to adhere to the PhytoSERM regimen.
* For females of reproductive potential: Negative pregnancy test and use of highly effective contraception by male partner for at least 1 month prior to screening and agreement to use such a method during study participation.

Exclusion Criteria:

* Use of isoflavone containing supplements.
* Known allergies to isoflavones or soy-based products.
* Montreal Cognitive Assessment total score \< 22.
* Pregnancy
* Use of estrogen or progestin compounds within 8 weeks of baseline.
* Use of investigational agent within 12 weeks of baseline.
* Concurrent neurologic, systemic, or psychiatric disease that would influence cognition or ability to provide informed consent and to participate.
* Known or suspected estrogen-dependent neoplasia (breast, ovarian and uterine cancers), active neoplastic disease, history of breast cancer, and endometrial hyperplasia.
* History within the last 5 years of any other primary or recurrent malignant disease, with the exception of resected cutaneous squamous cell carcinoma in situ, and basal cell carcinoma.
* History of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol, or substance abuse.
* Thrombophlebitis, thrombosis, thromboembolic disorders, myocardial infarction, ischemic heart disease, cerebrovascular accident, stroke, TIA.
* Current use of tobacco or a history of alcohol abuse.
* Use of anticoagulants.
* Chronic use of most benzodiazepines
* Use of drugs, herbs, or dietary supplements to treat menopausal or cognitive symptoms less than 8 weeks prior to baseline (e.g., SSRIs, rhubarb, red clover, licorice, kudzu, black cohosh, ginseng or other similar roots, etc.)
* Evidence of any significant clinical disorder or laboratory finding, including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality.
* Known allergy to soy-derived products/ proteins or branded over the counter products; hypersensitivity to estrogens or progestins.
```

## Arms

- **PhytoSERM** (EXPERIMENTAL) — Active intervention group
- **Placebo group** (PLACEBO_COMPARATOR) — Control group

## Interventions

- **PhytoSERM** (DIETARY_SUPPLEMENT) — PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
- **Placebo** (DRUG) — Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.

## Primary Outcomes

- **Hot Flash Composite score** _(time frame: Daily from baseline to week 24)_ — Composite score comprised by hot flash frequency and severity (sum of weekly hot flashes weighted by severity: mild, moderate, severe). Higher score indicates a bad outcome. No minimum or maximum values.

## Secondary Outcomes

- **Trail Making Test score** _(time frame: Baseline, week 4, 8, 12 and 24.)_
- **NIH Toolbox List Sorting Working Memory Test score** _(time frame: Baseline, week 4, 8, 12 and 24.)_
- **NIH Toolbox Picture Sequence Memory Test** _(time frame: Baseline, week 4, 8, 12 and 24.)_
- **NIH Toolbox Auditory Verbal Learning Test** _(time frame: Baseline, week 4, 8, 12 and 24.)_
- **NIH Toolbox Oral Symbol Digit Test** _(time frame: Baseline, week 4, 8, 12 and 24.)_
- **Pittsburgh Sleep Quality Index (PSQI)** _(time frame: Baseline, week 4, 8, 12, 18, 24 and 28.)_
- **Menopause Rating Scale score** _(time frame: At screening, weeks 12, 24 and 28.)_
- **Bone Mineral Density (BMD)** _(time frame: Baseline, week 12 and 24)_
- **Bone Mineral Content (BMC)** _(time frame: Baseline, week 12 and 24)_
- **Body Mass Index (BMI)** _(time frame: Baseline, week 12 and 24)_
- **Total Fat Mass (TFM)** _(time frame: Baseline, week 12 and 24)_
- **Total Lean Mass (TLM)** _(time frame: Baseline, week 12 and 24)_

## Locations (1)

- University of Arizona, Tucson, Arizona, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of arizona|tucson|arizona|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06186531.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06186531*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*